CN116997364A - 抗转铁蛋白受体融合蛋白及其使用方法 - Google Patents

抗转铁蛋白受体融合蛋白及其使用方法 Download PDF

Info

Publication number
CN116997364A
CN116997364A CN202280022750.1A CN202280022750A CN116997364A CN 116997364 A CN116997364 A CN 116997364A CN 202280022750 A CN202280022750 A CN 202280022750A CN 116997364 A CN116997364 A CN 116997364A
Authority
CN
China
Prior art keywords
seq
fusion protein
amino acid
acid sequence
ids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022750.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·阿尔圭洛
T·吉埃塞
G·坎南
M·S·卡里奥利斯
C·S·马洪
王军华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CN116997364A publication Critical patent/CN116997364A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280022750.1A 2021-02-11 2022-02-11 抗转铁蛋白受体融合蛋白及其使用方法 Pending CN116997364A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148543P 2021-02-11 2021-02-11
US63/148,543 2021-02-11
PCT/US2022/016229 WO2022174114A1 (en) 2021-02-11 2022-02-11 Anti-transferrin receptor fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN116997364A true CN116997364A (zh) 2023-11-03

Family

ID=82837358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022750.1A Pending CN116997364A (zh) 2021-02-11 2022-02-11 抗转铁蛋白受体融合蛋白及其使用方法

Country Status (6)

Country Link
US (3) US20240148866A1 (https=)
EP (1) EP4291246A4 (https=)
JP (1) JP2024507118A (https=)
CN (1) CN116997364A (https=)
MA (1) MA71665A (https=)
WO (1) WO2022174114A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120265319A (zh) * 2022-09-20 2025-07-04 丹娜-法伯癌症研究院 受体介导的胞吞作用用于膜蛋白和货物的靶向内化和降解
EP4630455A1 (en) 2022-12-05 2025-10-15 Sanofi Transferrin receptor binding proteins
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347910A1 (en) * 2001-10-16 2003-04-28 Symbiontics Inc. Methods and compositions for targeting proteins across the blood brain barrier
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
EP3088518A4 (en) * 2013-12-25 2017-09-20 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
SG11201901495YA (en) * 2016-08-25 2019-03-28 Jcr Pharmaceuticals Co Ltd Method for producing antibody fusion protein
KR102497564B1 (ko) * 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
AU2017386888B2 (en) * 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
CR20200129A (es) * 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
US20220002688A1 (en) * 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein

Also Published As

Publication number Publication date
US20240148866A1 (en) 2024-05-09
EP4291246A1 (en) 2023-12-20
MA71665A (fr) 2025-05-30
JP2024507118A (ja) 2024-02-16
WO2022174114A1 (en) 2022-08-18
US20250367284A1 (en) 2025-12-04
EP4291246A4 (en) 2024-12-11
US20250387477A1 (en) 2025-12-25

Similar Documents

Publication Publication Date Title
JP2023123757A (ja) トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
RU2731156C1 (ru) Гуманизированные антитела к cd19 человека и способы их применения
US20250367284A1 (en) Anti-transferrin receptor fusion proteins and methods of use thereof
ES2828482T3 (es) Anticuerpos contra el g-csfr y su uso
EP3737701A1 (en) Transferrin receptor-binding polypeptides and uses thereof
CN107074938A (zh) 抗‑α‑突触核蛋白抗体和使用方法
CN110352202A (zh) 抗pd-l1抗体和il-7融合蛋白
CN113950483B (zh) 抗hla-dq2.5抗体
KR20220156526A (ko) 조작된 항-her2 이중특이성 단백질
CN117801115A (zh) 抗-hla-dq2.5抗体及其在治疗乳糜泻中的用途
JP2023545707A (ja) スルホグルコサミンスルホヒドロラーゼ酵素を含む融合タンパク質及びその方法
US20220112258A1 (en) Bifunctional molecules with il-7 activity
WO2023192282A1 (en) Methods for treating brain glucose hypometabolism
EP4688837A1 (en) Abeta-targeting proteins and methods of use
TW202340459A (zh) 包含α—Ｌ—艾杜糖醛酸酶之融合蛋白及其方法
CN117715933A (zh) 抗vista的构建体及其用途
JP7089483B2 (ja) 修飾された抗テネイシン抗体及び使用方法
JP7690612B2 (ja) 抗ｍａｓｐ－２抗体及びその使用
JP2024534824A (ja) 操作された抗ｈｅｒ２二重特異性タンパク質
KR20240052019A (ko) 항-her2 항체 및 이의 사용 방법
HK40108627A (zh) 抗vista的构建体及其用途
CN121399164A (zh) 双重转运体及使用方法
EA051395B1 (ru) Слитые белки, содержащие ферменты сульфоглюкозамин-гидролазы, и связанные с ними способы
CN120265651A (zh) 用于生产蛋白质的方法
HK40103089A (zh) 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination